Red Blood Cells Derived from Whole Blood Treated with Riboflavin and UV Light Maintain Adequate Cell Quality through 21 Days of Storage.

Autor: Dimberg LY; Terumo BCT, Lakewood, Colorado, USA., Doane SK; Terumo BCT, Lakewood, Colorado, USA., Yonemura S; Terumo BCT, Lakewood, Colorado, USA., Reddy HL; Terumo BCT, Lakewood, Colorado, USA., Hovenga N; Terumo BCT, Lakewood, Colorado, USA., Gosney EJ; Terumo BCT, Lakewood, Colorado, USA., Tran M; Terumo BCT, Lakewood, Colorado, USA., Wilkinson S; Terumo BCT, Lakewood, Colorado, USA., Goodrich RP; Infectious Disease Research Center, Colorado State University, Fort Collins, Colorado, USA., Marschner S; Terumo BCT, Lakewood, Colorado, USA.
Jazyk: angličtina
Zdroj: Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie [Transfus Med Hemother] 2019 Aug; Vol. 46 (4), pp. 240-247. Date of Electronic Publication: 2019 Feb 22.
DOI: 10.1159/000495257
Abstrakt: Background: The Mirasol system for whole blood (WB) is a non-toxic, non-mutagenic pathogen reduction technology (PRT) that treats WB units with riboflavin (vitamin B 2 ) and ultraviolet (UV) light to alter nucleic acids, thereby reducing pathogen infectivity and inactivating white blood cells. This study evaluates the quality of red blood cells (RBCs) derived from WB treated with the Mirasol system.
Study Design and Methods: Paired units of WB were collected from 61 healthy donors. One unit per donor was treated with riboflavin and UV light and the other was used as an untreated control. RBCs were processed from the WB units and stored in AS-3 at 1-6°C for 21 days and sampled for in vitro analyses of RBC quality parameters.
Results: Several statistically significant differences were observed between test and control units, but values were overall within normal clinical ranges. After leukoreduction, the residual leukocyte count and RBC recovery met FDA requirements. The RBC units derived from treated WB maintained haemolysis below 1% through 21 days of storage.
Conclusion: RBCs derived from WB treated with the Mirasol system meet accepted FDA guidelines for RBC quality through 21 days of storage at 1-6°C.
Competing Interests: The views expressed in this manuscript are the authors' own views and do not represent an official position of their institutions or the organisations funding this research. All authors except R.P.G. are employees of Terumo BCT, the manufacturer of the Mirasol technology. R.P.G. is a former employee of Terumo BCT and is under a consulting agreement with Terumo BCT.
(Copyright © 2019 by S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz: